Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics with an Overweight rating and $13 price target. The type 1 diabetes market is large and SAB-142 could have a "significant opportunity as a potential disease modifying therapy," the analyst tells investors in a research note. The firm sees SAB's Phase 2b data in the second half of 2027 as the major catalyst for the stock and sees SAB-142's regulatory pathway as de-risked after Tzield's recent approval. SAB's $300M market capitalization underappreciates the $4B potential opportunity for SAB-142 as a therapy for type 1 diabetes prevention, contends Barclays.
